Single Nucleotide Polymorphism SNP Analysis ‎of Exon6Follistatin Gene Relatedtopolycystic ‎Ovarian Syndrome inThiQar Governorate‏.‏ by Jabaar, Enas Abd-Alkareem
Journal of University of Babylon, Pure and Applied Sciences, Vol.(26), No.(4): 2018 
392 
 
Single Nucleotide Polymorphism SNP Analysis 
of Exon6Follistatin Gene Relatedtopolycystic 
Ovarian Syndrome inThiQar Governorate. 
 
Enas Abd-Alkareem Jabaar 
College of Science , University of DhiQar  
Enaskareemenaskareem@yahoo.com  
 
Abstract 
Follistatin has been identifiedas a nominee gene for polycystic ovary syndrome (PCOS) from 
relationship studies. 
Acting to control the developmentof ovarian follicles and as an antagonist to aromatase action, 
changes in Follistatinrole or expression may affect main features of PCOS alteration. 
The aim of the recent study was to study the association of FST gene to define if 
genomicdifferencesarerelated with phenotypic structures of PCOS patients in a case–control suggestion 
study. 
Methods:This study involved 30 women with PCOS and 20 healthy women, whowerematched by 
their ageand anthropometric and biochemical profiles.The study was designed to examine theseparation 
of deoxyribonucleic acid (DNA), and genotype analysis was done for all the study participants using 
PCR-SNP. 
Results:Polymorphisms (SNPs) in the exon 6 FST gene region were determined for PCOS patients 
and controls, it was found that PCOS patientshad17 SNP in different samples, and after performing 
amino acid sequences alignment for these SNPs, it was observed that the last two SNPs of sample C12 
constituted a non-synonym mutation, and the functional conformation of the produced FST gene 
weremodified with regard to exon 6 in the genotype C12. When this exonic SNP appears in the three-
dimensional structure of the resulting proteins of C12 genotypes, the positively charged amino acid, 
Asp, is converted into another positively charged amino acid, His, in position 331 of the whole amino 
acid sequence of FST protein.The conclusionis that this, in turn doesn’t change the final phenotypic 
manifestation of the protein, and there was no alteration in the phenotypes of the PCOS patients. 
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 ةصلاخلا 
نيتاتسلوفلا فرعي ونا ىمع تلاصيوحلا ومن ىمع ةرطيسلا ىمع لمعي ونا ذا ضيابملا سيكت ضرمب اطابترا تانيجلا رثكا نم
كلذكو ضيبملا زيتامورلاا ميزنا ةيلاعف ىمع ةرطيسلا  ىلا يدؤي نيجلا اذى يف رييغت يأ ناو سيكتب تاباصملا ءاسنلا ةيضارما ةدايز
.تايعيبطلا ءاسنلا عم ةنراقم ضيابملا سيكت ضرمو روكذملا نيجلا نيب ةقلاعلا ةسارد وى ةيلاحلا ةساردلا نم فديلا ناو ضيابملا 
 ةساردلا ذى تنمضت03 باصم ةارماو ضيابملا سيكتب ة03  ةيريظملا ةيحانلا نم نينيب ةنراقملا تمت و ةباصم ريغ ةارما
.ةينيجلا تاريغتلا ةسارد كلذكو  ةينومريلا ريياعملا سايقو 
 ريغ قطانم يف رعش رويظ كلذكو نزولا يف ةدايزلا نم نيناعي ضيابملا سيكتب تاباصملا ءاسنلا نا ةساردلا جئاتن نم دجو دقل
 ايب بوغرم دوجو ظحول دقف ةينيجلا ةيحانلا نم اما تلاصيوحمل دلوملا نومريلا يف ناصقنو ينيتوملا نومرى يف ةدايزو71  ينيج ريغت
 دجو نيتوربلا يف ةممتحملا تاريغتلا عم ةينيجلا تاريغتلا هذى ةقباطم دعبو ضيابملا سيكتب تاباصملا ءاسنلا دنع طقف نا0  نم
طلا ىمست يتلا ةينيجلا تاريغتلا اضيا ةنحشلا بجوم نيتورب ىلا ةنحشلا بجوم نيتورب نم ريغتلا ىلا يدؤت  يتلا ةتماصلا ةيثارولا ةرف
 ضيابملا سيكت ةيضارما وا ةيريظملا تاريغتلا ىمع رثؤي لا ريغتلا اذى ونا لاا. 
 
الكممات المفتاحية: متلا زمة تكيس المبايض، جين الف ولستاتين، تتابع الني وكمي وتيدات. 
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Introduction  
Polycystic OvarySyndrome (PCOS) is considered one of most common 
endocrine complaints among femalesof childbearing age. This syndrome was first 
described by Leventhal and Stein, in1952. At thattime, it was known to be related to 
ovarian cysts.In 1990,the National Institute of Health estimated that this disorder 
affects 6-8 % of women in the world(March et al., 2010). This syndrome results in 
many complications, which includereduced fertility, obesity, excess hair growth, and 
an increased risk of developing type 2 diabetes (Kaushal et al, 2004) 
.DevelopingPCOS depends on the interaction of genetic and environmental factors 
(Wijeyaratne, 2011).Many genetic metabolic pathways have interacted in PCOS, like 
the steroid hormone metabolic pathway, the action of gonadotropins, and the 
metabolism of the hormone, insulin (Ewens et al., 2011).Many studies have been 
done,for example, one included 150 families to examine the genetic role in the 
occurrence of the disease. Researchers found that there are 37 genes that contribute to 
PCOS, evidence has indicated that the most common disease-causing gene is 
Follistatin (FST) (Urbanek et al, 1999).Follistatincontrolsactivin, which is 
responsiblefor follicular ovaryexpansion, reticence of theca cell androgen 
manufacture and increasesin bothinsulin secretionand the follicle stimulating hormone 
FSH secretion (Calvo et al., 2001).  FST is mainly produced in the granulosa cells of 
theantral follicle of the ovary, Follistatin mRNA is present within the main follicle 
during growth and declines during the atreticdevelopment (Lin et al., 
2003).Follistatinplays a main role in aromatase action in the granulosa cell, and also 
LH-stimulated progesterone relief from theca cells (Phillips and Krester, 1998). 
High levels of Follistatinin mice has resulted in a decline in follicular levels of 
FSH, both important phenotypes of PCOS (Urbanek et al., 2000). Many studies have 
found that there is a strong relationship between Follistatin and PCOS, as Follistatin 
islinkedto activin and impedes its work, which is stimulating FSH as they havefound 
that the genetic changesin the gene FST causes a relative reduction in FSH 
concentration in serum (Odunsi et al., 1999). On the other hand, FSTcontrols the 
growth of follicles in the ovariesand as an opponent to aromatase action, changes in 
Follistatinrole or utteranceresulting in maintopographies of PCOS, for example, 
decreasedthe levels of FSH, and weakenedthe growth of follicular and androgen 
synthesis . Follistatin, or activin-binding protein is a monomeric encoded by a single 
gene, FST, this gene is located on chromosome 5 q11.2 and receptors of this protein 
exist in most of the body tissues. However, the essential role of Follistatin is binding 
toActivin, which is a protein that works on the secretion, stimulation, and synthesis of 
follicle-stimulating hormones. Activin works also to regulate the menstrual cycle. 
Contrary to Activin, another protein called Inhibin works to inhibit the production of 
FSH (Jones et al, 2007).When first discovered, Follistatin was called FSH 
Suppressing Protein(FSP). It was isolated from the Follicular fluid, and it was noticed 
that it has an inhibitory effect on the anterior pituitary, and specifically on the 
secretion of follicle-stimulating hormone (Nakatani et al., 2008). Follistatin is 
secreted by cells in the anterior pituitary called folliculostellate cells (FS). Those cells 
are in contact with the other cells of the anterior pituitary, including Gonadotropic 
cells. In tissues, a cell proliferation is induced by Activin, and that's why Follistatin 
role is to regulate cell proliferation to prevent over proliferation of cells. Also 
Follistatin contributes tocell differentiation; the main role of Follistatin is inducing the 
differentiation of ovarian follicular cells, and also to work on the differentiation of 
estrogen producing granulosa cells (EC) from the grown follicle. Follistatin also 
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contributes to producing progesterone through stimulating progesterone producing 
large lutein cells (LLC) (Reis et al., 2007). 
Many studies have demonstrated that there's a strong connection between 
Follistatin and Polycystic Ovaries Syndrome, as Follistatin binds to Activinand affects 
its work which is to stimulate FSH,it was found that the excessive genetic changes of 
FST cause a decrease in the concentration of FSH in the blood serum. (Odunsi et al, 
1999). The purpose of thisresearch was to study the change in the nucleotide bases 
sequencing of exon 6 toFollistatin gene FST, and how that relates to PCOS. 
 
Materials and Methods 
Blood Sampling and Biochemical Study  
5 ml of blood was collected from a sample of 30 women who have PCOS, and 
who have been coming regularly to Obstetrics & Gynecology hospital of Bint-Alhoda 
(Thi–Qar province ) duringthe period between (November 2015 –April 2016). The 
ages of these women ranged from twenty to thirty years . Based on Rotterdam criteria 
(ASRMS ESHRE), these women underwent the following examinations. An 
ultrasound exam was done onthe twelfth day of the menstrual cycle to check for 
ovarian cysts. For diagnosing PCOS, the size of the ovary and the number of the 
follicles were examined in two groups ( healthy women and patient ) . They were also 
checked for lack or irregularity of ovulation, excessive secretion of Androgen 
(androgen excess), and menstrual irregularity (26 to 30 days). They also had no 
history of endocrine disorders and didn't use drugs or contraception. A sample of 20 
normal women also underwent the sameexaminations and proved to have normal 
ovaries. The blood samples weresplit into two portions. 3 ml of blood was put into 
atubewithout anticoagulant (EDTA), and lift it 30 minutethen the sample was 
centrifuged at room temperature to separate the blood serum (20 min/3000 rpm). Then 
the serum was stored under -20˚C until the examination was performed. The level of 
the hormones FSH, and LH weremeasured during the follicular phase,according to 
manufacturer’s instructions (BioMérieux, France). The other 2 ml portions of blood 
wereplaced in an anticoagulant (EDTA) tube. 
 
Genomic DNA Extraction 
The genomic DNA was isolated from blood using a Genomic DNA Mini Kit 
(Geneaid, Taiwan). The extracted genomic DNA was evaluated by 0.8% agarose gel 
electrophoresis in 1X TAE (40 mMTris acetate; 2 mM EDTA, pH 8.3) using 
Ethidium bromide (0.5 mg/ml), and quantified using a nanodrop (BioDrop µLITE, 
Biodrop, UK).  
 
PCR Primers Design 
One pair of primers was successfully designed to amplify the exon 6 of FST 
genetic locus using the NCBI primer BLAST online software (GenBank Acc. No. 
NG_028911.1). The designed oligonucleotide primer pair is; forward 5′- 
GAACACAAGAGCGCTTTTTATCTA -3′, and reverse 5′- 
TGCCATGTTTGAAAATATAAAATTG -3′, which was designed to amplify 1344bp 
bp to partially cover exon 6 of FST gene. 
 
PCR Analysis 
The PCR reaction was performed using AccuPower PCR premix (Cat # K-2012, 
Bioneer - Korea). The optimum annealing temperatures were determined empirically 
in our extracted DNA template using gradient PCR (ver. Mastercycler-nexus, 
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Eppendorf, 22331Hamburg). The amplification was startedby initial denaturation at 
94°C for 5 min, followed by denaturation at 94°C for 30 secondsto30 cycles of, 
annealing at 58.5°C for 30 seconds, and elongation at 72°C for 30 seconds, and was 
concluded with anending extension at 72°C for 5 minutes. After performing PCR 
thermocycling, PCR products were verified by electrophoresis on a 1.5% (w/v) 
agarose gel in 1X TBE buffer (2 mM of EDTA, 89 mM of Tris–Borate, pH 8.3), using 
a 2000-bp ladder (Cat # D-1010, Bioneer – South Korea) as a molecular 
massindicator for approval of the size of the PCR products. Gels were stained with 
ethidium bromide (0.5 mg/ml) and visualized with the gel image documentation 
system (ChemiDoc, Bio-Rad, USA). All SSCP non-suitable amplicons bands were 
eliminated. 
 
DNA Sequencing and Sequencing Analysis 
Each unique sample’s pattern for the amplified FST gene (1344bp) fragment 
was purified and sequenced from both ends (Macrogen Inc. Geumchen, Seoul, South 
Korea). Only vibrant chromatographs found from ABI sequence records were further 
examined, confirming that the annotation and differences are not because of PCR or 
sequencing artifacts. The reference sequences of exon 6/FST gene (GenBank acc. No. 
NG_028911.1) were recovered from the NCBI website 
(http://www.ncbi.nlm.nih.gov). The sequencing outcomes of the PCR products of 
different DNA sequence patterns were edited, aligned, and associated with their 
reference sequences using BioEdit Sequence Alignment Editor Software Version 7.1 
(DNASTAR, Madison, WI, USA). 
 
Protein Structure Designing 
The primary structure designing of each FST genotype was begun by 
mutating the available reference NCBI DNA sequences of exon 6/FST gene, by 
substituting each observed SNP into its reference sequences using BioEdit /Lasergene 
software to represent the non-synonymous C12 genotype. The whole amino acid 
sequences of the bovine FST protein were retrieved online from the protein data bank 
(www.rcsb.org). Thesetwo nucleic acid sequences were translated into amino acids in 
a reading frame correspondingto the reference FST amino acid sequences using the 
Expasy online program (http://web.expasy.org/translate/). Multiple amino acid 
sequence alignments weremade between the reference exon 6/FST amino acid 
sequences and its observed genotype using UniprotKB software 
(www.uniprotkb.org), and the results were represented using BioEdit /Lasergene 
software. The three-dimensional arrangement of the FST gene was constructed from 
the online three-dimensional model prediction software; protein homology/analogy 
recognition engine (Phere2), version 2.0 (www.sbg.bio.ic.ac.uk/phyre2). The virtual 
proposed changes within its corresponding mutants wereperformed by using PyMOL-
v1,7.0.1 software (www.shrodinger.com). 
 
Finding deleterious nsSNP(s) by the SIFT program 
sorting intolerant from tolerant  (SIFT) software forecasts whether 
replacement with any of the other amino acids is accepted or damaging for eachsite in 
the succumbed sequence (Patel et al., 2015). The SIFT prediction was given a 
tolerance index (TI) score ranging from 0.0 to 1.0,which was the normalized 
probability that the amino acid change was tolerated. A nsSNP with a TI score of 
V0.05 was considered to be deleterious i.e. amino acids with probabilities  
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< 0.05 were predicted to be harmful. The amino acid sequence of FST along with 
nsSNPs with corresponding amino acid positions were submitted to the SIFT program 
(http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html).  
 
Validation of the Functional Characterization of nsSNPs(s) by the PANTHER 
Program 
The SIFT predicted nsSNPs were validated by the PANTHER (protein 
analysis through evolutionary relationship) program (http:// 
www.pantherdb.org/tools/csnp). This tool guesses the probability of a particular non-
synonymous coding SNP to create a foundationfor a functional influence on the 
protein using Hidden Markov Models (HMM) based modeling and evolutionary 
relationship. It analyzes the subPSEC (substitution position-specific evolutionary 
conservation) mark based on an alignment of evolutionarily related proteins. The 
PSEP (position-specific evolutionary preservation) measures the length of time (in 
millions of years) a position of thecurrent protein has been preserved by tracing back 
to its reconstructed direct ancestors. The longer a position has been preserved, the 
more likely that it will have a deleterious effect. The thresholds we chose were: 
"probably damaging" (time > 450my, corresponding to a false positive rate of ~0.2 as 
tested on HumVar), "possibly damaging" (450my > time > 200my, corresponding to a 
false positive rate of ~0.4) and "probably benign" (time < 200my) (Tang and Thomas, 
2016). 
 
Statistical Analysis 
The results were statistically analyzed using Minitab (program) and with one 
ANOVA way test to calculate the mean ± Standard deviation (SD) and the results 
were compared between the women with PCOS and the control group under a 
significance level of 0.01. 
 
Results and Discussion 
The study was designed to engage the Follistatin (FST)gene and polycystic 
ovary syndrome (PCOS)  because there's a significant indication that there is a 
connection between FST gene and PCOS , as Follistatin was considered a likely 
cause. 
Follistatin is an activin-binding protein that deactivates the action of activin in 
vivo and in vitro and is stated in varioussites, countingthepituitary, adrenal 
cortex,ovary, and pancreas. Activin, a member of the transmuting growth element 
superfamily, controls the manufacture of androgens by thecal cells of the ovary, the 
growth of follicular, and the excretion of FSH by the pituitary and insulin by the 
pancreas. SinceFollistatinprevents the action of activin, changingFollistatin’saction 
would be a probableway to affect ovarian follicle growth, androgen synthesis, FSH 
release, and insulin secretion. All these events have been shown to be disturbed in 
PCOS links to activin and affect its work, which is to stimulate FSH, it was found that 
the excessive genetic change of FST causes a decrease of the concentration of FSH in 
the blood serum (Jones et al., 2007). 
 
Biochemical Study 
The results of ultrasound examinations of ovaries of women with PCOS 
showed that there was a largenumber of sacs that contained immature eggs sized 2-9 
mm. What is supposed to happen is that; each menstrual cycle, a sac grows to produce 
one mature egg sized 18-22 mm. But what actually happens here in the sampleis that a 
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largenumber of sacs grow at the same time and then they all stop growing midway, 
and so, none of these eggs ever reach the right size and pregnancy doesn't happen. 
Also the figure shows an enlarged uterus and the sacs appear as a string of pearls as 
shown in figure(1) 
 
 
Figure (1): shows a normal ovary on the left and a polycystic ovary on the right 
 
Table (1) shows the body mass of women with PCOS compared to women with 
normal ovaries. We notice that there is a calculated probability of the body mass of 
the women with PCOS54.70   ±  11.37on the significance level of p≤ 0.01.  
 
Table (1) shows the body mass of women with PCOS compared to healthy 
women 
p≤ 0.01 
 
The remarkable increase of the body mass which may reach the degree of 
obesity, is attributed to the fact that most women with PCOS have insulin resistance 
which leads to an excess of body fat and an increase in the body mass index,especially 
in the abdomen (Venkatesan, Dunaif and Corbould, 2001), the study assumed that 
free fatty acids released from fat cells affect the extraction of the insulin hormone 
from the liver, and consequently prevents the body cells from absorbing glucose  
(Kelley, 2002; Holte et al., 1994). This study’s resultsagreed with of the research 
done byWijeyaratneand his colleagues (2011) who noticed an increase in the body 
mass of women with PCOS and attributed it to a deficiency in body metabolism , also 
the study of Maryam et al (2015) showed an increase in the body mass of women with 
PCOS. The study was done on women aged over 35 years old. This increase is a result 
of a deficiency in metabolism and may lead to a deficiency in ovulation, and they 
suggested reducing the body weight to improve ovulation and regulate the menstrual 
cycle.Table(2) shows a comparison between women with PCOS and healthy women 
on the basis of the concentrations of pituitary hormones; follicle stimulating hormone 
 
Body mass 
groups Mean±Std. deviation Significant 
PCOS women 54.70   ±  11.37      0.00 
Healthy women 48.31  ±   12.19 
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FSH,and luteinizing hormone LH, we notice in this table the relative difference in the 
concentrations of these two hormones, as the LH concentration is above the normal 
when compared to the concentration of FSH (elevated LH to FSH ratio). The level of 
LH in the women with PCOS was 6.51 ± 2.96 before the release of the egg. This 
refers to a probability of (P<0.01) in the level of LH in the women with PCOS when 
compared to the normal women’s group. 
 
Table (2) shows a comparison between the level of LH and of FSH in women 
with PCOS and healthy women. 
 
Parameters  groups Mean±Std. deviation Significant 
Follicle stimulating 
hormone (FSH) 
PCOS women 5.08 ± 0.98 0.001 
Healthy women 8.62 ± 3.1 
Luteinizing 
hormone (LH) 
PCOS women 6.51 ± 2.96 0.00 
Healthy women 3.88 ± 1.44 
p≤ 0.01 
 
as a result, the ovulation doesn't happen and the egg becomes a cyst and 
consequently the menstrual cycle and the pregnancy are delayed. (Asuncion, 2000; 
Louis, 2007). The increase in LH happens because the ovary couldn't secrete 
Gonadotropin hormones like Estrogen through negative feedback which is under the 
control of (hypothalamic- pituitary axis) (Louck et al., 2000). 
Asthe levels of LH hormone stay high in patients with PCOS, this leads to the 
level of FSH becoming lower when compared to the level of LH. Becausethe LH/FSH 
ratiobecomes high in blood, the secretion of estrogen will decrease and the secretion 
of Androgens will increase. One of these Androgens is Testosterone, which is 
secreted from the ovary and causes the ovary to fail in stimulating the growth and 
maturity of ovarian follicles and producing graafian follicles,with normalsizes of 18-
22 mm, and so, ovulation becomes rare and the menstrual cycle becomes irregular and 
pregnancy is delayed. (Altuntas et al., 2006). This study agreed with the study of 
(Anlakash et al., 2007; Legroset al., 2002;GulabKanwar et al., 2015) at a remarkable 
elevation of luteinizing hormone (LH) level was found when compared to follicle-
stimulating hormone (FSH), and this elevation causes imbalance of the other 
hormones relating to the hypothalamus-pituitary-ovary axis.In another study an 
elevation in the level of LH was found in the serum of women with PCOS. This 
elevation may cause oversecretion of androgens by the theca interstitial cells 
(Dhanalakshmi et al., 2012) . 
When comparing the concentrations of FSH in women with PCOS with 
womenin thehealthy group 5.08 ± 0.98,alternatively the results showed that there's a 
probability value of (P > 0.01) between the concentration rate of LH in women with 
PCOS and women with normal ovaries, and this study agreed with (Iwasa et al., 2009; 
Fakhoury et al., 2012; Saxena et al., 2012) but FSH stimulates the growth of ovarian 
follicles and so, its level drops below the normal levels, it leads to ovarian failure 
because it is related to estrogen through a negative feedback mechanism in women 
with PCOS (Robert et al., 2009). The current study agreed with the study of 
(Fakhoury et al., 2012), as this study found an elevation in the LH / FSH ratio and at 
the same time a reduction in the level of FSH hormone in the serum of Saudi women 
with PCOS. 
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Also, in the study of Holteand his colleagues (1994) they noticed that the level 
of Follicle-stimulating hormone was lower than normal through measuring its 
concentration in the follicular phase, which indicates the importance of its role in 
ovulation and that its reduction causes irregularity of ovulation and leads to PCOS. 
 
Genotyping of FST SNPs 
Nucleotide sequences from all eight observed genotypes revealed several SNPs. 
The pattern and nature of each SNP detected by sequencing indicated that the 
genotype of healthy women beginning with the sample 1 that was called C1 has five 
SNPs (C 860 G, T 894 C, C 911 G, C 914 G, and T 949 G) (Fig. 4, A), C2 has three 
SNPs (A 959 T, T 1202 G, and A 1136 T) (Fig. 4, B), C4 has only one SNP (T 1202 
G) (Fig. 4, C), C6 has two SNPs (T 529 G, and T 1202 G) (Fig. 4, D), while the 
genotype of PCOS women in samples :  C7 has only one SNP (T 1177 C) (Fig. 4, E),  
C8 has two SNPs (C 804 A, and C 1095 A) (Fig. 4, F), C9 has only one SNP (A 1167 
T) (Fig. 4, G), while C 12 has two SNPs (G 334 C, and G 339 C) (Fig. 4, H). 
However, after performing amino acid sequences alignment for these SNPs, it was 
found that the last two SNPs of C12 constitute a non-synonym mutation (Fig. 5), and 
the functional conformation of the produced FST gene is modified with regard to exon 
6 in the genotype C12 (Fig. 6). When this exonic SNP appears in the three-
dimensional structure of the resulting proteins of C12 genotypes, the positively 
charged amino acid, Asp, is converted into another positively charged amino acid, 
His, in the position 331 of the whole amino acid sequences of FST proteins. This, in 
turn doesn’t change the conformation in the final phenotypic manifestation of the 
protein (Fig. 6, A and B). Conversely, the conversion of the uncharged amino acid, 
Gln, into a positively charged amino acid, His, in the position 322 of the whole amino 
acid sequences may have a drastic effect on the final confirmation of the FST protein 
and its consequent function(Fig. 6, A and B). To determine the functional effects of 
nsSNPs in FST genes, two widely used in silico tools, specifically SIFT and 
PANTHER were utilized. If a marker is found to be associated with the disease, and 
the marker is a nsSNP, prediction tools can provide independent evidence as to 
whether the nsSNP itself contributes to disease. The two examined nsSNP 
substitutions wereidentified as tolerated by the SIFT program with a score of 0.08 and 
0.16 for both D331H and 0.16 respectively (table 3), and this result is differentfrom 
another result that found another exon not be exon 6 that the FASTA format of 
protein was assumedto the nsSNP Analyzer device and the difference E152Q 
andC239S was specified as a response in the SNP data field. E152Qalteration is 
neutral, as well asthe C239S sources disease. 
PANTHER – Evolutionary analysis of coding SNPs: theprotein sequence was 
analyzed for theE152Q and C239S SNPs. The probability that a givenvariant will 
affect a harmfulresultof aprotein functionis projected by Pdeleterious such that a 
subPSEC score of −3corresponds to a Pdeleterious of 0.5. (Palanisamy et al., 2010). 
These two nsSNPs were further validated by the PANTHER program. However, 
it was found by the later program that both nsSNPs were classified as possibly 
damaging. Unfortunately, and according to our knowledge, no previous proteomic 
studies were done thatfocused on bovine exon 6 of the FST protein so it is impossible 
to compare our results with any other study. Thus, thisdata provides the first evidence 
about the nature of such possiblemutations in this gene. However, it is not necessary 
that all variants have a maindamaging functional influence and some may be well 
tolerated. However, nsSNPs which are linked to illnesses or other phenotypes often 
have some molecular significance (Johnson et al., 2005). They may alter enzyme 
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activity, undermine protein structures, or unsettle protein connections. In the current 
study, after the extraction of DNA and replication through Polymerase Chain 
Reaction technique, the gene was multiplied with the use of a particular primer. The 
size of the gene was 1344 bp in both the patients’ samples and the normal women, as 
this gene is important for it produces the protein of Follistatin which is very 
important. Any change or mutation in one base (SNP) leads to a change inthe gene 
and of its production of proteinaccording to our knowledge. Another study found 
many mutations were found in this gene and were related to PCOS (Liaoet al., 2000). 
Another study, which related to SNP of Exon 6 of gene FST it was noticed that the 
base of 243 changed from T to A in women with PCOS. (MARGRIT et al., 2015). 
 A recent study disagrees with the study of Urbanek et al(2000) that detectedthat 
coding areas and some introns of the Follistatin gene were sequenced, disclosing at 
least 17 polymorphisms; however, 16 of them were erratic, making a significant 
influence of these alternatives to the pathogenesis of hyperandrogenismdoubtful. 
Moreover, the merelypublic polymorphism found, situated in exon 6 but not 
translated, was not linked with PCOS when correcting for multiple analysis, and the 
authors concludedthat aids to the etiology of PCOS from the Follistatin gene, if any, 
are minor. 
In theoreticaldisagreement, no mutations in the Follistatingene have been found 
in Chinese PCOS patients definite bymenstrualdysfunction, hyperandrogenism, and 
polycysticovaries (Liao et al., 2000), and the only mutation wasestablished in a chain 
ofpatients from Spain, a silent G951A variant, was equallyconcentrated in PCOS 
patients and in vigorous women (Calvo et al., 2001). 
In another study,the exon 6 variant (T-to-A) alteration is located 78 nucleotides 
downstream of the end codon in the 39 untranslated area of exon 6 and, therefore, are 
not translated. Exon 6 is then again spliced to products of two transcripts. One 
transcript holds the exon 6 variant site, whereas the other transcript does not. Thus, 
the functional magnitude of the exon 6 variant is indistinct; andthis variant has been 
earlierpronounced by Shimasaki et al. (1988). 
In previous studies,that roster of intronic and identical SNPs, with 
theirnucleotide site, amino acid alteration information, anddbSNP link, is provided for 
additionalinvestigation. Scientistswere unable to recognize any transmutation of the 
stimulating orpreventing type in the whole coding region of Follistatingene in 64 
patients with PCOS. Therefore, transmutations in thecodingsites of the Follistatin 
gene may not be a publicreason of PCOS in the populace studied. However, it 
isthinkable that mutations may be present in the controllingareaof the gene, which 
should be partitioned once its sequenceis known. Also, it would be abundantly helpful 
tostudythe presense ofmutations in PCOS patients inother culturalareas, principally of 
European background, as itwas in this people that the connection between the 
Follistatingene and PCOS was recognized(Liao et al., 2000). 
The conclusions in this study are that awide sequencing of the Follistatin 
gene hasknown variants at 17 sites in eight testers, but none of these appear to be 
probable etiological causes in PCOS. Only sample 8, called C12 variant has two 
nsSNPs compared with the other seven variants, which are not interpreted, and other 
strictlyconnected polymorphic sites external the Follistatin gene,. Even at exon 6, 
where the strongest proof was found, the verdicts are, at most, a touch significant; and 
they are not significant whenalteredfor testing a larger sample. Even though this 
discovery reduces provision for the Follistatin gene that linked with PCOS patient 
itself. 
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Table (3):shwos Functional validations of nsSNPs inFST gen (D, Q amino acid) 
using SIFT and PANTHER programs. 
Amino acid 
change 
SIFT prediction SIFT score PANTHER 
prediction 
PNATHER 
score (PSEC) 
D331H Tolerated   0.08 possibly damaging 361 
Q332H Tolerated   0.16 possibly damaging 455 
 
 
Figure (2) represents Agarose gel electrophoresis the result of gene FST of the 
normal women group. With a concentration of 1.5 %) volts=70, amps= 50, time= 
1hour( 
 
 
 
Figure (3) represents Agarose gel electrophoresis the result of gene FST of the 
group of women with PCOS with a concentration of 1.5 % (volts=70, amps= 50, 
time= 1hour) 
 
Journal of University of Babylon, Pure and Applied Sciences, Vol.(26), No.(4): 2018 
232 
 
 
Fig. (4): chromatogram sequencing results of Homo sapiens FST gene, exon no. 6. A) C – G, T – C, C – 
A, C – G, and T – G SNPs at positions 860, 894, 911, and 949 respectively in C1 genotype of Homo 
sapiens FST gene, exon no. 6. B): A – T, T – G, and A – T SNPs at positions 959, 1202, and 1136 
respectively in C2 genotype of Homo sapiens FST gene, exon no. 6. C): T - G SNP at position 1202 in C4 
genotype of Homo sapiens FST gene, exon no. 6. D): T – G SNPs at positions 529, and 1202 respectively 
in C6 genotype of Homo sapiens FST gene, exon no. 6. E): T – C SNPs at positions 1177 in C7 genotype 
of Homo sapiens FST gene, exon no. 6. F): C – A SNPs at positions 804 and 1095 in C8 genotype of 
Homo sapiens FST gene, exon no. 6. G): A – T SNP at position 1167 in C9 genotype of Homo sapiens 
FST gene, exon no. 6. H): G – C SNPs at position 334 and 339 respectively in C12 genotype of Homo 
sapiens FST gene, exon no. 6. 
 
 
Figure: (5) Multiple sequence alignment of amino acids sequences of FST protein of Homo 
sapiens. The dark grey shaded sequences refer to the similar amino acid sequences. The dots 
refer to the nature of differences in the amino acid sequences. Only C12 variant has two non-
synonym SNPs compared with the other seven variants. 
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Fig. 6 Postulated three-dimensional structure of the human FST protein showing the 
change of amino acid “D” or “Asp” (in the position 331) and the amino acid “Q” or 
“Gln” (in the position 332) of the reference protein (A), into amino acid “H” in both 
positions in only C12 protein variants. 
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